Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 25 · below the Ichimoku cloud · RSI 46 · MACD below its signal
| 12.18 | 52-week high | +106.09% |
| 7.19 | Previous month high | +21.66% |
| 6.10 | R3 (classic) | +3.16% |
| 6.08 | Previous month low | +2.88% |
| 6.04 | Previous week high | +2.20% |
| 6.00 | R2 (classic) | +1.58% |
| 5.96 | R1 (classic) | +0.79% |
| 5.91 | Price now | |
| 5.91 | Previous day high | −0.00% |
| 5.86 | Pivot | −0.79% |
| 5.82 | S1 (classic) | −1.58% |
| 5.77 | Previous day low | −2.37% |
| 5.72 | S2 (classic) | −3.16% |
| 5.68 | S3 (classic) | −3.95% |
| 5.61 | Previous week low | −5.04% |
| 4.75 | 52-week low | −19.63% |
None of the 29 investors followed here reported a position in VALN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VALN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for VALN.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.4 | 20.4 | -43.6 | -13.9 | 16.2 | -16.3 | -5.0 | 26.8 | -1.8 | -4.4 | −33.0% | ||
| 2025 | 32.2 | 16.8 | -0.6 | -5.4 | 0.9 | -11.4 | 29.6 | 20.4 | 37.9 | -24.0 | 0.9 | -5.7 | +101.7% |
| 2024 | -21.4 | -12.9 | 11.5 | -5.9 | 21.7 | -22.7 | 4.9 | -0.4 | -17.5 | -6.5 | -28.3 | 8.0 | −57.8% |
| 2023 | 5.4 | -12.6 | -12.5 | -7.9 | 20.7 | 29.4 | 0.5 | -5.7 | -17.2 | -1.6 | 1.9 | -10.8 | −18.5% |
| 2022 | -38.6 | -4.0 | 4.8 | -24.1 | -5.8 | -7.4 | -10.8 | -8.2 | -45.7 | 31.7 | -3.8 | -0.5 | −77.1% |
| 2021 | 1.4 | 8.5 | 85.4 | -40.8 | 42.1 | 44.7 | -14.0 | +113.7% |
Buy / hold / sell counts
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.